Baricitinib reduces mortality of hospitalised COVID patients by 46 percent
New data shows Lilly’s Olumiant (baricitinib) significantly reduces the risk of death in hospitalised COVID-19 patients receiving invasive mechanical ventilation or ECMO.
List view / Grid view
New data shows Lilly’s Olumiant (baricitinib) significantly reduces the risk of death in hospitalised COVID-19 patients receiving invasive mechanical ventilation or ECMO.
The ACTIV-3 sub-study will evaluate the safety and efficacy of the AZD7442 synthetic antibody combination in at least 150 participants with mild-to-moderate COVID-19.
Operation Warp Speed and the NIH are funding the expansion of two trials evaluating the efficacy of convalescent plasma therapy in hospitalised COVID-19 patients.
A collaboration between Brigham and Women's Hospital and Vanderbilt University Medical Center looks to advance the application of AI in health...
Researchers at Vanderbilt University Medical Center have used an integrated imaging approach to probe an invasive Staphylococcus aureus (‘staph’) infection in a mouse model, revealing new insights about staph infections that can be broadly applied to other diseases.